UNSPSC 51283907: Sulfacitine or sulfacytine

This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T795873AJP. European Medicines Agency schedules Sulfacitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10690MIG. Sulfacitine generally arises in the molecular formula C12H14N4O3S. The term SULFACITINE is an International Non-Proprietary Name or INN. SULFACITINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Sulfacitine or sulfacytine bears US NLM identifiers UMLS ID C0262960 and NCI Concept Code C47734. SMILES: CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N.

UNSPSC 51283907 Sulfacitine or sulfacytine, a Commodity code, shows minimal relevant recent state and local procurement activity. The single opportunity explicitly tagged to this pharmaceutical code is a Seminole County, Florida IFB for naloxone and drug deactivation systems—products unrelated to sulfacitine—suggesting a classification mismatch rather than active demand for the code's nominal product. The three other recent opportunities in the source (Tampa Fire Department medical and first aid supplies, Texas HHS pharmaceutical direct-to-manufacturer inquiry, and Minnesota MMCAP generic multi-source pharmaceuticals) span medical supplies, pharmacy benefit program structuring, and broad pharmaceutical commodity contracting, none of which centers on sulfacitine specifically.

No substantive volume, geographic concentration, issuing-body pattern, or contract frequency emerges from these records to support a pursue decision. State and local health departments, county health agencies, and cooperative purchasing alliances remain the primary institutional buyers of pharmaceutical commodities, but sulfacitine does not register as a current procurement focus at any of them. The Seminole County naloxone solicitation (IFB 60459723LAS, due July 26, 2023) and the Minnesota MMCAP generic pharmaceuticals RFP (due March 26, 2026) represent active health-sector buying, but neither targets sulfacitine. Unless your firm supplies sulfacitine as a secondary line within broader pharmaceutical or first-responder supply agreements, or anticipates demand from specific state Medicaid programs or county health systems, this code warrants monitoring rather than active pursuit.